Stay updated on Efficacy Safety Nemolizumab in Atopic Dermatitis Clinical Trial
Sign up to get notified when there's something new on the Efficacy Safety Nemolizumab in Atopic Dermatitis Clinical Trial page.
Latest updates to the Efficacy Safety Nemolizumab in Atopic Dermatitis Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe website has been updated from version 2.11.0 to 2.11.2, indicating new features or improvements.SummaryDifference0.0%
- Check22 days agoChange DetectedThe website has been updated to Revision v2.11.0, while the previous version v2.10.5 has been removed, along with a notice regarding delays in displaying study record information.SummaryDifference0.5%
- Check30 days agoChange DetectedClinicalTrials.gov is addressing delays in displaying study record information, and the website has been updated to version 2.10.5, replacing the previous version 2.10.3.SummaryDifference0.4%
- Check44 days agoChange DetectedThe website has been updated from version 2.10.2 to 2.10.3.SummaryDifference0.0%
- Check58 days agoChange DetectedThe study results posted on August 14, 2024, detail the efficacy and safety of nemolizumab in treating moderate-to-severe atopic dermatitis after a 16-week treatment period, highlighting significant clinical response metrics such as IGA success and EASI-75 improvement.SummaryDifference98%
- Check65 days agoChange DetectedThe website has been updated from version 2.10.0 to 2.10.2, indicating new features or improvements.SummaryDifference0.1%
Stay in the know with updates to Efficacy Safety Nemolizumab in Atopic Dermatitis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Efficacy Safety Nemolizumab in Atopic Dermatitis Clinical Trial page.